Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000851536 | SCV001370881 | pathogenic | Phenylketonuria | 2020-06-01 | reviewed by expert panel | curation | The c.1316-1G>A variant in PAH is a null variant (canonical +/- 1 or 2 splice sites) in a gene where LOF is a known mechanism of disease. It is predicted to result in skipping of coding exon 13, which is a key domain of the enzyme (PVS1_Strong). It is absent from ethnically diverse control databases, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). It has been previously reported in seven Ugyur probands (PMID: 31355225): three homozygotes with mild PKU; one compound heterozygote with classic PKU in trans with the p.R413P variant (Pathogenic per ClinGen PAH working group); one compound heterozygote with classic PKU in trans with the p.R243Q variant (Pathogenic per ClinGen PAH working group); one compound heterozygote with mild PKU in trans with the p.A300S variant (Pathogenic per ClinGen PAH working group); and one compound heterozygote with mild PKU in trans with the p.E182K (Likely Pathogenic per ClinGen PAH working group) variant (PM3_VeryStrong). (In all cases, phase was confirmed by parental testing.) In all cases, BH4 deficiency was formally excluded by urinary pterin analysis (PP4_Moderate). It is reported pathogenic in Clinvar (ID 625286) by one lab, for PKU; no further information is given. |
Center for Molecular Medicine, |
RCV000851536 | SCV000924698 | pathogenic | Phenylketonuria | 2019-03-08 | no assertion criteria provided | clinical testing |